Physician
Oxy-Gen Laboratory LLC
Oxy-Gen Laboratory LLC was paid $1.12M by Medicaid between Jan 2019 and Jul 2023, across 41 billing codes. Its largest line is 81406, — 18% of everything it billed.
33Billing provider infoOXY-GEN LABORATORY LLC
PEACHTREE CORNERS, GA 30092
PEACHTREE CORNERS, GA 30092
33aNPI1730628439assigned 02/15/2017
33bProvider typeMolecular Genetic Pathology (Pathology) Physician
28Total paid$1.12M
24GClaims6,441
24DCodes billed41
24AFirst – last monthJan 2019 – Jul 2023
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 2,733 | $1.00M | |
| 2020 | 2,292 | $75K | |
| 2021 | 818 | $40K | |
| 2022 | 267 | $3K | |
| 2023 | 331 | $2K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 81406 | 18% | 119 | 104 | $204K | |
| 81298 | 12% | 99 | 95 | $139K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 9.0% | 2,303 | 1,278 | $101K |
| 81295 | 8.0% | 99 | 95 | $89K | |
| 81292 | 6.9% | 90 | 86 | $78K | |
| 81321 | 5.8% | 86 | 80 | $66K | |
| 81408 | 5.4% | 61 | 59 | $60K | |
| 81201 | 5.1% | 55 | 51 | $58K | |
| 81317 | 5.1% | 54 | 51 | $57K | |
| 81226 | 3.8% | 126 | 121 | $43K | |
| 81405 | 3.5% | 109 | 96 | $39K | |
| 81404 | 2.5% | 112 | 99 | $29K |
29 more codes
| 81225 | 2.5% | 125 | $28K | |
| 81403 | 2.0% | 94 | $22K | |
| 81230 | 1.5% | 125 | $17K | |
| 81231 | 1.5% | 125 | $17K | |
| 81227 | 1.5% | 125 | $17K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 270 | $10K |
| 81355 | <1% | 125 | $8K | |
| 0100U | <1% | 64 | $6K | |
| 81293 | <1% | 94 | $6K | |
| 81296 | <1% | 81 | $5K | |
| 81299 | <1% | 81 | $5K | |
| 81318 | <1% | 70 | $5K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 190 | $4K |
| 81401 | <1% | 12 | $2K | |
| 87581 | <1% | 235 | $2K | |
| 87486 | <1% | 236 | $2K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 86 | $957.76 |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 140 | $609.21 |
| 87563 | <1% | 77 | $602.77 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 54 | $514.92 |
| 87265 | <1% | 231 | $498.52 | |
| 87481 | <1% | 89 | $280.72 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 80 | $140.36 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 80 | $140.36 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 80 | $137.32 |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 0% | 12 | $0.00 |
| 81322 | 0% | 24 | $0.00 | |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | 0% | 48 | $0.00 |
| 81479 | Unlisted molecular pathology procedure | 0% | 75 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTOURE, JEAN FRANCOIS (MANAGER)